Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of...
Neuroscience
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024...
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod...
Koneksa Appoints Dr. Jessie Bakker as Vice President of Clinical Development
NEW YORK--(BUSINESS WIRE)--#biotech--Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Jessie Bakker, M.S., Ph.D., as Vice President...
Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic
-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome...
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
World-First Introduction of Home Oral Glucose Tolerance Testing Service for Gestational Diabetes Sees University Hospital Southampton Improve Test Accessibility and Yield Maximum User Preference Scores
OXFORD, UK / ACCESSWIRE / February 21, 2024 / Digital clinical diagnostics and diabetes home testing provider Digostics revealed today...
PharmAla Data to be Published in ACS Chemical Neuroscience
Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research...
Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2...
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human...
Virtua Health partners with care.ai for enterprise-wide implementation of AI-Enabled Virtual Care Solutions for Patients
Virtua Health will leverage care.ai's Smart Care Facility Platform and Always-Aware ambient sensors to enhance patient care, support nursing staff,...
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on...
Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain
Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain King Faisal Specialist Hospital...
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel...
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11...
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
Magdalena aiming to submit Investigational New Drug application in 2024 to the FDA for this next-generation psychoactive prescription drug candidate...
Deliberate AI Announces its Depression and Anxiety Model, AI-COA™, is the First AI/ML Initiative to Be Accepted into the FDA’s ISTAND Pilot Program to Advance Drug Development
NEW YORK--(BUSINESS WIRE)--Deliberate AI, a digital health technology company that delivers precision measurement of mental health through AI, today announced...